These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 7916094)
21. [Peripheral neuropathy unmasked by therapy with adrenal cortex hormones during myalgia-eosinophilia syndrome related to L-tryptophan]. Moreaud O; Mezin P; De Saint Victor JF; Noelle B; Berger F; Pellat J Presse Med; 1994 Jun; 23(24):1138. PubMed ID: 7971839 [No Abstract] [Full Text] [Related]
22. Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan. Greenberg AS; Takagi H; Hill RH; Hasan A; Murata H; Falanga V J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):264-6. PubMed ID: 8708033 [No Abstract] [Full Text] [Related]
23. [Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake]. Grangeia Tde A; Schweller M; Paschoal IA; Zambon L; Pereira MC J Bras Pneumol; 2007; 33(6):747-51. PubMed ID: 18200378 [TBL] [Abstract][Full Text] [Related]
24. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. Shapiro S J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181 [TBL] [Abstract][Full Text] [Related]
32. [Acute pleuropericarditis with eosinophilia after ingestion of tryptophan]. Dell'Isola B; Rezgui N; Thiollieres JM; Labrousse J; Lissac J; Valcke JC Rev Med Interne; 1993 May; 14(5):353-4. PubMed ID: 8235154 [No Abstract] [Full Text] [Related]
33. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York. Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862 [TBL] [Abstract][Full Text] [Related]
34. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. Kilbourne EM; Philen RM; Kamb ML; Falk H J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184 [TBL] [Abstract][Full Text] [Related]
35. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study. McKeon P; Swanwick G; Manley P Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779 [TBL] [Abstract][Full Text] [Related]
36. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome. Naylor S; Williamson BL; Johnson KL; Gleich GJ Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088 [TBL] [Abstract][Full Text] [Related]
37. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome. Marchman HB; Gleason CB; Shaw JC Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317 [TBL] [Abstract][Full Text] [Related]
38. [A case from practice (233). Eosinophilic myalgia syndrome]. Hefti U; Steiger U Schweiz Rundsch Med Prax; 1991 Dec; 80(50):1421-2. PubMed ID: 1749884 [No Abstract] [Full Text] [Related]
39. Tryptophan. Current status and future trends for oral administration. Kaufman LD; Philen RM Drug Saf; 1993 Feb; 8(2):89-98. PubMed ID: 8452659 [No Abstract] [Full Text] [Related]
40. The eosinophilia myalgia syndrome: to be or not to be. Espinoza LR Semin Arthritis Rheum; 1997 Jun; 26(6):781-4. PubMed ID: 9213375 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]